<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04467853</url>
  </required_header>
  <id_info>
    <org_study_id>BM2L201910</org_study_id>
    <nct_id>NCT04467853</nct_id>
  </id_info>
  <brief_title>A Clinical Study to Evaluate CAR-T Cell-based Medicinal Product in the Treatment of Advanced Gastric Cancer</brief_title>
  <official_title>A Phase 1, Open-Label Study Evaluating the Safety, Tolerability and Efficacy of LCAR-C18S, an CAR-T Cell Therapy Targeting Claudin18.2 in Patients With Advanced Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai East Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nanjing Legend Biotech Co.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai East Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, single-arm, open-label, Phase 1 dose finding and extension study to&#xD;
      evaluate the safety, tolerability, pharmacokinetics, and anti-tumor efficacy profiles of the&#xD;
      cell-based LCAR-C18S (hereinafter &quot;LCAR-C18S&quot;) in subjects with Claudin18.2-positive advanced&#xD;
      gastric adenocarcinoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 21, 2020</start_date>
  <completion_date type="Anticipated">November 2024</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-limiting toxicity (DLT) and incidence, severity, and type of treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>90 days post infusion</time_frame>
    <description>Dose-limiting toxicity (DLT) refers to a drug-related toxicity during treatment with the drug, the severity of which is clinically unacceptable, limiting the further escalation of drug dose. An adverse event refers to any untoward medical occurrence in a clinical investigation subject administered a pharmaceutical product (investigational or non-investigational), which does not necessarily have a causal relationship with the treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>RP2D regimen finding</measure>
    <time_frame>90 days post infusion</time_frame>
    <description>Recommended Phase 2 dose (RP2D)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Chimeric Antigen Receptor T (CAR-T) Positive Cell Concentration</measure>
    <time_frame>2 years post infusion</time_frame>
    <description>Venous blood samples will be collected for measurement of CAR-T positive cellular concentration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR) after administration</measure>
    <time_frame>2 years post infusion</time_frame>
    <description>Objective Response Rate (ORR) is defined as the proportion of subjects who achieve CR or PR after treatment via LCAR-C18S cell infusion, and the objective tumor response rate will be calculated for patients with measurable disease per RECIST 1.1 only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of remission (DOR) after administration</measure>
    <time_frame>2 years post infusion</time_frame>
    <description>Duration of Remission (DOR) is defined as the time from the first documentation of remission (PR or better) to the first documented disease progression evidence (according to RECIST 1.1) of the responders (who achieve PR or better response).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progress Free Survival (PFS) after administration</measure>
    <time_frame>2 years post infusion</time_frame>
    <description>Progression Free Survival (PFS) is defined as the time from the date of first infusion of the LCAR-C18S to the first documented disease progression (according to RECIST 1.1) or death (due to any cause), whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) after administration</measure>
    <time_frame>2 years post infusion</time_frame>
    <description>Overall Survival (OS) is defined as the time from the date of first infusion of LCAR-C18S to death of the subject.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR) after administration</measure>
    <time_frame>2 years post infusion</time_frame>
    <description>Disease Control Rate (DCR) is defined as the proportion of patients with complete response, partial responses and stable disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response (TTR) after administration</measure>
    <time_frame>2 years post infusion</time_frame>
    <description>Time to Response (TTR) is defined as the time from the date of first infusion of LCAR-C18S to the date of the first response evaluation of the subject who has met all criteria for PR or better.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">34</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>chimeric Antigen Receptor T cell LCAR-C18S Cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>LCAR-C18S cells</intervention_name>
    <description>Prior to infusion of the LCAR-C18S, subjects will receive a premedication regimen (IV infusion of cyclophosphamide 300 mg/m2 and fludarabine 30mg/m2 once daily (QD) for 3 days; if the subject have a creatinine clearance of 40-70 mL/min/1.73 m2, or for patients &gt; 70 years of age and with a performance status score of 1, dose reduction of fludarabine to 25 mg/m2 and cyclophosphamide to 250 mg/m2 will be allowed). Infusion of LCAR-C18S is scheduled 5 to 7 days after the initiation of the premedication regimen.</description>
    <arm_group_label>chimeric Antigen Receptor T cell LCAR-C18S Cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The subjects have been fully informed of the possible risks and benefits of&#xD;
             participating in the study and have signed the informed consent form;&#xD;
&#xD;
          2. Age 18-75 years;&#xD;
&#xD;
          3. Histologically confirmed recurrent or metastatic advanced gastric adenocarcinoma&#xD;
             (including gastric adenocarcinoma of the gastro-oesophageal junction);&#xD;
&#xD;
          4. Immunohistochemistry of tumor tissue samples indicates Claudin18.2 positive ;&#xD;
&#xD;
          5. Previous adequate standard of care recommended by the National Comprehensive Cancer&#xD;
             Network (NCCN 2019 V3) or the Chinese Society of Clinical Oncology (CSCO 2019)&#xD;
             guidelines for gastric cancer, or comparable standard-of-care regimen assessed by the&#xD;
             investigator; treatment failure or intolerability; subjects who have a positive test&#xD;
             result for HER2 must have been treated with trastuzumab or are not recommended to use&#xD;
             trastuzumab as assessed by the investigator;&#xD;
&#xD;
          6. Subjects with evaluable recurrent or metastatic lesions according to past medical&#xD;
             history data or imaging findings;&#xD;
&#xD;
          7. ECOG performance status score of 0-1;&#xD;
&#xD;
          8. Expected survival ≥ 3 months;&#xD;
&#xD;
          9. Hematology meets the following criteria: WBC ≥ 2.5 × 109/L; ANC ≥ 1.5 × 109/L; HGB ≥ 9&#xD;
             g/dL; PLT ≥ 75 × 109/L (Subjects must not have received any growth factor or blood&#xD;
             transfusion support within 7 days prior to laboratory tests);&#xD;
&#xD;
         10. Blood biochemistry meets the following criteria: TBIL ≤ 1.5 × ULN (≤ 3 × ULN in&#xD;
             subjects with liver metastasis); AST and ALT ≤ 3.0 × ULN (≤ 5 × ULN in subjects with&#xD;
             liver metastasis); serum creatinine ≤ 1.5 × ULN, creatinine clearance &gt; 50 mL/min/1.73&#xD;
             m2 (per Cockcroft-Gault formula);&#xD;
&#xD;
         11. Coagulation meets the following criteria: INR &lt; 1.5 × ULN, PT, APTT &lt; 1.5 × ULN;&#xD;
&#xD;
         12. Women of childbearing age must have a negative blood pregnancy test; subjects of&#xD;
             childbearing potential must use effective contraception for ≥ 1 year after the final&#xD;
             study treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Receipt of the following anti-tumor therapies prior to apheresis:&#xD;
&#xD;
               -  Cytotoxic therapy within 14 days&#xD;
&#xD;
               -  Small molecule targeted therapy within 14 days or at least 5 half-lives,&#xD;
                  whichever is shorter&#xD;
&#xD;
               -  Treatment with monoclonal antibody within 21 days&#xD;
&#xD;
               -  Immunomodulatory therapy within 7 days&#xD;
&#xD;
               -  Radiation therapy within 14 days&#xD;
&#xD;
          2. Previous CAR-T cell therapy or other cell therapies or therapeutic tumor vaccination&#xD;
             against any target;&#xD;
&#xD;
          3. Any previous therapy targeting Claudin18.2;&#xD;
&#xD;
          4. Brain metastases with central nervous system symptoms;&#xD;
&#xD;
          5. Pregnant or lactating women;&#xD;
&#xD;
          6. Uncontrolled diabetes;&#xD;
&#xD;
          7. Oxygen is required to maintain adequate blood oxygen saturation;&#xD;
&#xD;
          8. Gastric perforation, pyloric obstruction, complete biliary obstruction, complete or&#xD;
             incomplete intestinal obstruction requiring clinical intervention, or pleural effusion&#xD;
             or peritoneal effusion requiring clinical intervention;&#xD;
&#xD;
          9. Clinically significant liver disorders (including liver cirrhosis, active viral&#xD;
             hepatitis or other hepatitis);&#xD;
&#xD;
         10. Positive for any one of hepatitis B surface antigen (HBsAg), hepatitis B virus&#xD;
             deoxyribonucleic acid (HBV DNA), hepatitis C antibody (HCV-Ab), or human&#xD;
             immunodeficiency virus antibody (HIV-Ab);&#xD;
&#xD;
         11. Severe underlying diseases, such as:&#xD;
&#xD;
               -  Evidence of serious active viral or bacterial infection, or uncontrolled systemic&#xD;
                  fungal infections&#xD;
&#xD;
               -  Active or unstable auto-immune diseases or history of auto-immune diseases within&#xD;
                  3 years and that may relapse&#xD;
&#xD;
               -  Evident clinical evidence of dementia or mental status changes&#xD;
&#xD;
         12. Significant bleeding tendency, such as haemorrhage of digestive tract, coagulation&#xD;
             disorders, and hyposplenism;&#xD;
&#xD;
         13. New York Heart Association (NYHA) Class III or IV congestive heart failure or left&#xD;
             ventricular ejection fraction (LVEF) &lt; 50%; unstable angina, myocardial infarction or&#xD;
             coronary artery bypass grafting (CABG) in the past 6 months; history of severe&#xD;
             non-ischemic cardiomyopathy; or severe uncontrolled arrhythmia;&#xD;
&#xD;
         14. Other malignant tumors in addition to gastric adenocarcinoma (including the&#xD;
             gastro-oesophageal junction), except for as below&#xD;
&#xD;
               -  Malignant tumor was cured and no active symptoms more than two years before&#xD;
                  apheresis;&#xD;
&#xD;
               -  Non-melanoma skin cancer or cervical cancer in situ, no evidence of progression&#xD;
                  disease ;&#xD;
&#xD;
         15. Patients with chronic diseases requiring treatment with systemic corticosteroids or&#xD;
             other immunosuppressive agents; use of systemic corticosteroid hormone (≥ 70 mg of&#xD;
             prednisone or equivalent dose of other corticosteroids) or other immunosuppressive&#xD;
             agents within 7 days prior to apheresis, with the exception of topical, ocular,&#xD;
             intra-articular, intranasal, and inhalational corticosteroids; or a brief course of&#xD;
             corticosteroids for prophylaxis (e.g., prophylaxis for contrast dye allergy)&#xD;
&#xD;
         16. Had a stroke or epilepsy within 6 months prior to signing ICF;&#xD;
&#xD;
         17. Receipt of live attenuated vaccine within 4 weeks prior to apheresis;&#xD;
&#xD;
         18. Subjects who have undergone major surgery within 2 weeks prior to apheresis or are&#xD;
             scheduled to undergo surgery during the study or within 2 weeks after study treatment&#xD;
             (Note: Subjects who plan to undergo a surgery under local anesthesia may participate&#xD;
             in this study);&#xD;
&#xD;
         19. Known allergy to excipients and related adjuvants (including but not limited to DMSO&#xD;
             and dextran-40) of the study drug;&#xD;
&#xD;
         20. Any condition that, in the opinion of the investigator, will make the subject&#xD;
             unsuitable for participation in this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jin Li, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai East Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jin Li, MD,PhD</last_name>
    <phone>+86</phone>
    <phone_ext>13761222111</phone_ext>
    <email>lijin@csco.org.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shiyu Hua, bachelor</last_name>
    <phone>+86</phone>
    <phone_ext>15040297604</phone_ext>
    <email>Shiyu.Hua@legendbiotech.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Anhui Provincial Hospital</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xinghua Han</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai East Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>China/Shanghai</state>
        <zip>200126</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jin Li, MD, PhD</last_name>
      <phone>86</phone>
      <phone_ext>13761222111</phone_ext>
      <email>lijin@csco.org.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Artemed Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jun Zhou, MD, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 1, 2020</study_first_submitted>
  <study_first_submitted_qc>July 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 13, 2020</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

